Kids Health First is closely monitoring COVID-19 updates from the leading authorities across the globe, including:
Please check back often for new developments and community advisories as they become available.
CDC Director Rachel Walensky endorses the ACIP recommendation-On June 18,2022 the Advisory Committee on Immunization Practices met to the discuss the FDA's recommendation on the EUA of both the Pfizer-BioNTech and Moderna COVID-19 vaccines for children 6 months thru 5 years of age. Click here for more information.
FDA is one step closer to EUA of COVID vaccines for children under age 5-On June 15, 2022 the committee of independent vaccine experts voted unanimously to recommend Moderna and Pfizer’s shots for use in infants through toddlers. The FDA will likely accept the recommendation moving closer to FDA approval.Click here for more information.
FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) is tentatively scheduled to meet on June 15, 2022. This meeting will be to discuss both the Pfizer-BioNTech vaccine for children aged 6m–4 years and the Moderna vaccine for children aged 6m– 5 years. CDC’s Advisory Committee on Immunization Practices (ACIP) is anticipated to meet within several days of VRBPAC, assuming FDA authorization; the meeting(s) will be posted here once scheduled. Click here for more information.
Pfizer-BioNTech reports strong immune response in children under 5 years of age following a third dose of the COVID-19 vaccine-On May 23, 2022 Pfizer reported that "based on toppling data, three doses of the Pfizer-BioNTech COVID-19 Vaccine met all immunobridging criteria required for Emergency Use Authorization." Click here for more information.
CDC recommends that all individuals age 5 and older receive a COVID-19 vaccine booster-On May 19, 2022 following a meeting with the CDC Advisory Committee on Immunizations Practices', the CDC expanded eligibility of a COVID-19 vaccine booster to everyone 5 years of age and older. For children 5 to 11 years of age, the CDC recommends that they receive a booster shot at least 5 months after completing the initial Pfizer-BioNTech vaccinations series. Click here for more information.
FDA expands eligibility for Pfizer-BioNTech COVID-19 vaccine booster for children 5-11 years old-On May 17, 2022 the FDA approved a single booster dose of the Pfizer-BioNTech COVID-19 at least 5 months after completion of the primary series. Click here for more information.
CMS announces updates on COVID-19 vaccinations and distribution-On May 6, 2022 CMS announced updated recommendations on COVID-19 vaccinations, distribution and Medicaid and CHIP reporting requirements and implications. Click here for more information.
FDA announces new restrictions on J & J COVID-19 vaccine-On May 5, 2022 the FDA announced new restrictions for the J & J COVID vaccine, limiting the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older due to issues related to blood clots. For more information click here.
Moderna asks the FDA for authorization of its two dose regimen of the COVID-19 booster in children under the age of 6-On April 27,2022 Moderna requested EUA authorization for its COVID-19 vaccine for younger children. The FDA is expected to make a recommendation as early as June. Click here for more information.
Pfizer announces results for COVID-19 booster in children 5-11 years of age-On April 14, 2022, Pfizer published the positive results in studies related to the COVID-19 booster vaccine in children ages 5-11. They plan to request EUA for this booster in the coming days from the FDA. Click here for more information.
The FDA announces EUA of first breathalyzer test in detecting COVID-On April 14, 2022, the FDA announced the emergency use authorization of a breathalyzer test which can detect SARS-CoV-2 infection. The test can be performed in doctor’s offices, hospitals, or mobile testing sites. Click here for more information.
Moderna announces preliminary results for COVID-19 vaccine for children under 5 years of age-On March 23, 2022, Moderna announced it would be requesting EUA for its vaccine for younger children from the FDA in coming weeks. Click here for more information.
FDA Delays Approval of COVID vaccine for children under 5-On February 11, 2022, the FDA delayed Pfizer's request to approve the emergency use authorization of their COVID-19 vaccine for children under the age of 5. The FDA is seeking clinical data on the evaluation of a third dose before moving forward. Click here for more information.
Pfizer-BioNTech Initiates Rolling Submission EAU of COVID vaccine for children under 5-On February 1, 2022 the FDA requested that Pfizer submit a rolling submission for emergency use authorization for their COVID-19 vaccine for children ages 6 months through 4 years. Click here for more information.
AAP addresses parents' concern about the Omicron variant in a newly released article-On January 21, 2022, www.healthy children.org provided information and advice for parents concerned about the transmissibility and affect of the Omicron variant on children. Click here for more information.
Effectiveness of Pfizer-BioNTech Vaccine against MIS-C-On January 7, 2022 the CDC reported that in a study involving of 24 pediatric hospitals across the country, the Pfizer-BioNTech vaccine showed a high level of effectiveness against MIS-C in children ages 12-18. "Receipt of 2 doses of Pfizer-BioNTech vaccine is highly effective in preventing MIS-C in persons aged 12–18 years. These findings further reinforce the COVID-19 vaccination recommendation for eligible children." Click here for more information.
CDC updates masking guidelines-On January 14, 2022 the CDC updated its guidelines on masks for all individuals. Click here for more information.
CDC clarifies recommendations for isolation and quarantine-On January 9, 2022 the CDC clarified its recommendations on isolation and quarantine for those exposed to or positive for COVID-19. Click here for those updated guidelines.
CDC expands booster shot eligibility for 12-17 year olds-On January 5, 2022 the CDC endorsed the ACIP recommendation to expand eliegility of booster doses to 12-17 year olds five months after their initial Pfizer-BioNTech vaccination series. Click here for more information.
FDA authorizes first booster for COVID-19 for 12-15 yr. olds-On January 3, 2022, the FDA authorized use of a booster of the Pfizer COVID-19 vaccine for children ages 12-15. The CDC will review this recommendation later this week. Click here for more information.
CNN reports 16- and 17-year-olds are now eligible for a Pfizer/BioNTech Covid-19 vaccine booster-On December 9, 2021 CNN reported that the US Food and Drug Administration authorized the Pfizer/BioNTech Covid-19 vaccine for use as a booster in people ages 16 and 17, and the US Centers for Disease Control and Prevention recommended it for this age group. Click here for more information.
CDC: Booster Vaccines-On November 29, 2021 the CDC announced that everyone over the age of 18 should receive a COVID-19 booster vaccine. Click here for more information.
CDC: What you need to know about variants-On November 27, 2021, the CDC explains what you need to know about variants, including the newly identified Omicron variant. As of this date, no known cases of the Omicron variant have been discovered in the U.S. Stay tuned for developing news. Click here for more information.
CDC: Interim Guidance for Fully Vaccinated People- On November 19, 2021 the CDC released an updated version of their Interim Public Health Recommendations for Fully Vaccinated People. Click here to view the updated recommendations.
CDC: The Center for Disease Control advises vaccines for children ages 5-11-On November 2, 2021, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation that children 5 to 11 years old be vaccinated against COVID-19 with the Pfizer-BioNTech pediatric vaccine. Click here for more information.
Pfizer: COVID-19 vaccine produces significant immune response in children ages 5-11 years- On September 20, 2021 Pfizer and BioNTech announced on Monday that their COVID-19 vaccine is safe in children ages 5-11 years and produces a significant immune response. “We are encouraged by Pfizer-BioNTech’s announcement and look forward to reviewing the data from the clinical trial,” said AAP President Lee Savio Beers, M.D., FAAP. Click here for more information.
American Academy of Pediatrics Cautions Against Off-label Use of COVID-19 Vaccines in Children Under 12- On August 23,2021 the FDA finalized the full approval of the Pfizer-BioNTech COVID-19 vaccine for ages 16 and older. While questions may now arise about the administration of the vaccine off-label for children aged 11 and younger, who currently have no available vaccine, the AAP strongly discourages that practice. Click here for more information.
10.28.20– Ransomware Activity Targeting the Healthcare and Public Health Sector
The Cybersecurity and Infrastructure Security Agency (CISA), the Federal Bureau of Investigation (FBI), and the U.S. Department of Health and Human Services (HHS) have credible information of an increased and imminent cybercrime threat to U.S. hospitals and healthcare providers.
CISA, FBI, and HHS have released AA20-302A Ransomware Activity Targeting the Healthcare and Public Health Sector that details both the threat and practices that healthcare organizations should continuously engage in to help manage the risk posed by ransomware and other cyber threats. The advisory references the joint CISA MS-ISAC Ransomware Guide that provides a ransomware response checklist that can serve as a ransomware-specific addendum to organization cyber incident response plans.
In addition to these materials regarding the most recent ransomware threat to the Healthcare and Public Health Sector, the HHS Office for Civil Rights’ Fact Sheet: Ransomware and HIPAA provides further information for entities regulated by the HIPAA Rules.
CISA, FBI, and HHS are sharing this information in order to provide a warning to healthcare providers to ensure that they take timely and reasonable precautions to protect their networks from these threats. CISA encourages users and administrators to review CISA’s Ransomware webpage for additional information.
HHS Revises Definition of “Lost Revenue,” Clarifies Definition of “Reporting Entity,” and Expands Phase III Eligibility
On October 22, the Department of Health and Human Services (HHS) issued revised instructions regarding permitted uses of Provider Relief Fund (PRF) payments. The legislation creating the PRF restricts its use to “healthcare-related expenses or lost revenues that are attributable to coronavirus” and requires recipients to report on their use of funds. Read our detailed explanation of the HHS revisions here.
10.21.20- CDC Update COVID-19 Guidance
|The Centers for Disease Control (CDC) updated its guidance regarding COVID-19 testing (namely, a recommendation that asymptomatic persons should get tested) and the many considerations employers should make when reopening buildings after they’ve been closed or reduced in operations.|
New Report: U.S. Schools Have Avoided Spike in COVID-19 Cases
Reuters recently reported Friday, Oct. 2, that U.S. schools from kindergarten to high school have avoided a spike in COVID-19 cases, noting reassuring data that shows you can open schools safely when you put in place the right measures and have control of community spread. Medical experts say the real test is coming as students in large densely-populated cities such as New York and Miami return to classrooms.
The Centers for Disease Control (CDC) updated its guidance regarding COVID-19 testing (namely, a recommendation that asymptomatic persons should get tested) and the many considerations employers should make when reopening buildings after they’ve been closed or reduced in operations.
Georgia Health News reports a growing number of parents are increasingly uncomfortable with taking their children to the doctor. Given that Georgia is a COVID-19 hot spot and now has more than 260,000 confirmed cases, some parents feel the risk is too great. This post features comments from Dr. Keyana Washington- a KHF physician with Gwinnett Pediatrics and Adolescent Medicine and ,Dr. Sally Goza- President of the AAP.
Georgia AAP Partners with DPH to Promote Well Child Care– 8/12/20 The Georgia Chapter has partnered with the Georgia Department of Public Health on a social media campaign to promote the need for children to go to their pediatricians for well child care.
Updated Guidance for Discontinuing Isolation and Testing After COVID-19 Recovery
The Centers for Disease Control and Prevention updated guidance related to discontinuing isolation and testing after recovery. This guidance has implications for patients returning to you for care and for individuals returning to work or school.
For more information, refer to the Georgia Department of Public Health memo dated Wednesday, July 29, 2020.
The Georgia Chapter of the American Academy of Pediatrics (AAP) School Health Committee has developed a toolkit that can serve as a template for how the pediatrician can become involved in school re-openings.
We do capture site browsing history to improve our website for future visitors!